Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment

Next Previous
X
Search
Trial Profile

A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENESTFreedom
  • Sponsors Novartis; Novartis Farma; Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 30 May 2021 Planned End Date changed from 19 Feb 2025 to 20 Feb 2025.
    • 08 Dec 2020 Results (n=215) of the long-term outcomes after a 5-year follow-up from this study are presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2020 According to Seattle Cancer Care Alliance (SCCA), media release, data from this study will presented at the 62nd Annual Meeting of the American Society of Hematology, which is being held virtually December 5-8, 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top